64 related articles for article (PubMed ID: 3103387)
1. Dopamine receptor function in Parkinson's disease--in vivo studies with prolactin responses.
Laihinen A; Rinne UK
Adv Neurol; 1987; 45():249-52. PubMed ID: 3103387
[No Abstract] [Full Text] [Related]
2. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
Díaz F; Liberman C; Chariá P
Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
[TBL] [Abstract][Full Text] [Related]
3. Function of dopamine receptors in young-onset Parkinson's disease: prolactin response.
Kostic VS; Marinkovic Z; Filipovic S; Momcilovic D
Mov Disord; 1993 Apr; 8(2):227-9. PubMed ID: 8474497
[TBL] [Abstract][Full Text] [Related]
4. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P
J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149
[TBL] [Abstract][Full Text] [Related]
5. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum.
Fuxe K; Strömberg I; Popoli P; Rimondini-Giorgini R; Torvinen M; Ogren SO; Franco R; Agnati LF; Ferré S
Adv Neurol; 2001; 86():345-53. PubMed ID: 11553995
[No Abstract] [Full Text] [Related]
6. The extracerebral dopamine antagonist domperidone block the suppressive effect of bromocriptine on prolactin and TSH secretion in man.
Svet-Moldavsky I; Svet-Moldavsky G; Zinzar S; Holland J; Vergara C; Arlin Z; Koziner B; Clarkson B
Biomedicine; 1981 Oct; 35(5):142-4. PubMed ID: 6797487
[TBL] [Abstract][Full Text] [Related]
7. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
Elsworth JD; Roth RH
Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
[TBL] [Abstract][Full Text] [Related]
8. Sustained elevation of serum prolactin by metoclopramide: a clinical model of idiopathic hyperprolactinemia.
Healy DL; Burger HG
J Clin Endocrinol Metab; 1978 May; 46(5):709-14. PubMed ID: 122286
[No Abstract] [Full Text] [Related]
9. Function of dopamine receptors in Parkinson's disease: prolactin responses.
Laihinen A; Rinne UK
Neurology; 1986 Mar; 36(3):393-5. PubMed ID: 3081830
[TBL] [Abstract][Full Text] [Related]
10. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
Seeman P; Guan HC; Van Tol HH; Niznik HB
Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
[TBL] [Abstract][Full Text] [Related]
11. A neuroendocrinological investigation of patients with senile demantia of Alzheimer type. Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration.
Fujita M; Shimizu T
Bull Osaka Med Sch; 1986 Oct; 32(2):73-84. PubMed ID: 3122863
[No Abstract] [Full Text] [Related]
12. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
[No Abstract] [Full Text] [Related]
13. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
Bennett JP; Wooten GF
Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
[TBL] [Abstract][Full Text] [Related]
14. Prolactin secretion in Parkinson disease.
Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
16. Tuberoinfundibular dopaminergic function in Parkinson's disease.
Franceschi M; Camerlingo M; Perego L; Bottacchi E; Truci G; Mamoli A
Eur Neurol; 1988; 28(3):117-9. PubMed ID: 3133213
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
[TBL] [Abstract][Full Text] [Related]
18. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
19. Hypothalamic dysfunction in Parkinson's disease patients.
Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
[TBL] [Abstract][Full Text] [Related]
20. Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
Ueda H; Sato K; Okumura F; Inoue A; Nakata Y; Ozaki N; Yue JL; Misu Y
Biomed Pharmacother; 1995; 49(4):169-77. PubMed ID: 7669936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
